BRAF and melanoma: Although systematic studies have not been performed in thyroid cancers, studies in melanoma demonstrated that rare BRAF mutations located in the kinase domain of the protein (positions A598 to K601 in the protein) do respond well to kinase inhibitors such as vemurafenib and dabrafenib [11,39,40].